Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Endocrine 1Breast 1

Conditions

Neoplasms 8Breast Neoplasms 8Multiple Myeloma 6Giant Cell Tumor of Bone 6Prostatic Neoplasms 5Fractures, Bone 4Neoplasm Metastasis 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Osteoporosis 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Bone Neoplasms 2Bone Metastases 2Bone Diseases 2Thyroid Neoplasms 1Recurrence 1Parathyroid Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Kidney Neoplasms 1Hypercalcemia 1Humoral Hypercalcemia Of Malignancy 1Hormone Refractory Prostate Cancer 1Hodgkin Disease 1

Interventions

Zoledronic Acid 3Denosumab 3Letrozole 2Toremifene 1Risedronic Acid 1Kyphoplasty 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Bone Diseases, Metabolic × Denosumab × Clear all
NCT00089661 2018-10-17

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Amgen

Phase 3 Completed
252 enrolled 13 charts
Breast

Bone Diseases, Metabolic, Breast Neoplasms

NCT00980174 2018-10-17

Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis

Amgen

Phase 3 Completed
242 enrolled 19 charts
Endocrine

Bone Diseases, Metabolic, Osteoporosis, Multiple Endocrine Neoplasia Type 1

NCT00925600 2017-05-30

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Amgen

Phase 3 Completed
769 enrolled 21 charts
Genitourinary

Bone Diseases, Metabolic, Cataract, Neoplasms, Osteoporosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡